Format

Send to

Choose Destination
JAMA Intern Med. 2015 Dec;175(12):1992-4. doi: 10.1001/jamainternmed.2015.5868.

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

Author information

1
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
2
Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland.
PMID:
26502403
DOI:
10.1001/jamainternmed.2015.5868
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center